FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023355225> ?p ?o ?g. }

• W2023355225 endingPage "1166" @default.
• W2023355225 startingPage "1160" @default.
• W2023355225 abstract "In patients with diabetes, intensive glycaemic control reduces microvascular complications. However, severe hypoglycaemia frequently complicates intensive glycaemic control. Blood biomarkers that predict successful intensification of glycaemic control in patients with type 2 diabetes without the development of severe hypoglycaemia would advance patient care. In patients who received intensive treatment for type 2 diabetes from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, we hypothesised that insulin deficiency and islet autoantibodies would be associated with severe hypoglycaemia and failure to achieve near-normal glycaemia (HbA1c <6.0% [42 mmol/mol]).A nested case-control design was used. Cases (n = 326) were defined as participants having severe hypoglycaemia and failure to achieve an HbA1c level of <6.0% (42 mmol/mol) prior to the ACCORD transition or death. Controls (n = 1,075) were those who achieved an HbA1c level of <6.0% (42 mmol/mol) prior to the ACCORD transition or death without severe hypoglycaemia. Each case was matched (for race, age and BMI) by up to four controls. Baseline insulin deficiency (fasting C-peptide ≤0.15 nmol/l) and islet autoantibodies (glutamic acid decarboxylase [GAD], tyrosine phosphatase-related islet antigen 2 [IA2], insulin [IAA] and zinc transporter 8 [ZnT8]) were measured. Conditional logistic regression with and without adjustment for age, BMI and diabetes duration was used on the full cohort and after removal of patients who died and their respective controls.Severe hypoglycaemia accompanied by an inability to achieve an HbA1c level of <6.0% (42 mmol/mol) was associated with insulin deficiency (adjusted OR 23.2 [95% CI 9.0, 59.5], p < 0.0001), the presence of IAA autoantibodies or baseline insulin use (adjusted OR 3.8 [95% CI 2.7, 5.3], p < 0.0001), GAD autoantibodies (OR 3.9 [95% CI 2.5, 6.0], p < 0.0001), IA2 autoantibodies (OR 16.7 [95% CI 3.9, 71.6], p = 0.0001) and ZnT8 autoantibodies (adjusted OR 3.9 [95% CI 1.2, 12.4], p = 0.02).C-peptide and islet autoantibodies may serve as biomarkers to predict the risk of severe hypoglycaemia during intensification of type 2 diabetes treatment.ClinicalTrials.gov NCT00000620 (original ACCORD study)." @default.
• W2023355225 created "2016-06-24" @default.
• W2023355225 creator A5003552905 @default.
• W2023355225 creator A5018666743 @default.
• W2023355225 creator A5028196119 @default.
• W2023355225 creator A5067464347 @default.
• W2023355225 creator A5089855065 @default.
• W2023355225 date "2015-02-05" @default.
• W2023355225 modified "2023-09-26" @default.
• W2023355225 title "Biomarkers related to severe hypoglycaemia and lack of good glycaemic control in ACCORD" @default.
• W2023355225 cites W1522863980 @default.
• W2023355225 cites W1965800980 @default.
• W2023355225 cites W1967314259 @default.
• W2023355225 cites W1974442416 @default.
• W2023355225 cites W1983269691 @default.
• W2023355225 cites W1997042793 @default.
• W2023355225 cites W2001286026 @default.
• W2023355225 cites W2003754488 @default.
• W2023355225 cites W2032402557 @default.
• W2023355225 cites W2049583719 @default.
• W2023355225 cites W2074308333 @default.
• W2023355225 cites W2076573528 @default.
• W2023355225 cites W2097995302 @default.
• W2023355225 cites W2100202103 @default.
• W2023355225 cites W2102312517 @default.
• W2023355225 cites W2106407805 @default.
• W2023355225 cites W2107353084 @default.
• W2023355225 cites W2107648636 @default.
• W2023355225 cites W2114437291 @default.
• W2023355225 cites W2145962271 @default.
• W2023355225 cites W2153957843 @default.
• W2023355225 cites W2156555887 @default.
• W2023355225 cites W2156888511 @default.
• W2023355225 cites W2158744581 @default.
• W2023355225 cites W2169041612 @default.
• W2023355225 cites W2171155649 @default.
• W2023355225 cites W4243663251 @default.
• W2023355225 cites W4250647894 @default.
• W2023355225 cites W4254695749 @default.
• W2023355225 doi "https://doi.org/10.1007/s00125-015-3512-0" @default.
• W2023355225 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4416999" @default.
• W2023355225 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25652389" @default.
• W2023355225 hasPublicationYear "2015" @default.
• W2023355225 type Work @default.
• W2023355225 sameAs 2023355225 @default.
• W2023355225 citedByCount "17" @default.
• W2023355225 countsByYear W20233552252015 @default.
• W2023355225 countsByYear W20233552252016 @default.
• W2023355225 countsByYear W20233552252017 @default.
• W2023355225 countsByYear W20233552252018 @default.
• W2023355225 countsByYear W20233552252019 @default.
• W2023355225 countsByYear W20233552252020 @default.
• W2023355225 countsByYear W20233552252021 @default.
• W2023355225 countsByYear W20233552252022 @default.
• W2023355225 crossrefType "journal-article" @default.
• W2023355225 hasAuthorship W2023355225A5003552905 @default.
• W2023355225 hasAuthorship W2023355225A5018666743 @default.
• W2023355225 hasAuthorship W2023355225A5028196119 @default.
• W2023355225 hasAuthorship W2023355225A5067464347 @default.
• W2023355225 hasAuthorship W2023355225A5089855065 @default.
• W2023355225 hasBestOaLocation W20233552251 @default.
• W2023355225 hasConcept C126322002 @default.
• W2023355225 hasConcept C134018914 @default.
• W2023355225 hasConcept C159654299 @default.
• W2023355225 hasConcept C163764329 @default.
• W2023355225 hasConcept C165220095 @default.
• W2023355225 hasConcept C203014093 @default.
• W2023355225 hasConcept C2777180221 @default.
• W2023355225 hasConcept C2779306644 @default.
• W2023355225 hasConcept C2781232474 @default.
• W2023355225 hasConcept C50382708 @default.
• W2023355225 hasConcept C555293320 @default.
• W2023355225 hasConcept C71924100 @default.
• W2023355225 hasConcept C72563966 @default.
• W2023355225 hasConceptScore W2023355225C126322002 @default.
• W2023355225 hasConceptScore W2023355225C134018914 @default.
• W2023355225 hasConceptScore W2023355225C159654299 @default.
• W2023355225 hasConceptScore W2023355225C163764329 @default.
• W2023355225 hasConceptScore W2023355225C165220095 @default.
• W2023355225 hasConceptScore W2023355225C203014093 @default.
• W2023355225 hasConceptScore W2023355225C2777180221 @default.
• W2023355225 hasConceptScore W2023355225C2779306644 @default.
• W2023355225 hasConceptScore W2023355225C2781232474 @default.
• W2023355225 hasConceptScore W2023355225C50382708 @default.
• W2023355225 hasConceptScore W2023355225C555293320 @default.
• W2023355225 hasConceptScore W2023355225C71924100 @default.
• W2023355225 hasConceptScore W2023355225C72563966 @default.
• W2023355225 hasIssue "6" @default.
• W2023355225 hasLocation W20233552251 @default.
• W2023355225 hasLocation W20233552252 @default.
• W2023355225 hasLocation W20233552253 @default.
• W2023355225 hasLocation W20233552254 @default.
• W2023355225 hasOpenAccess W2023355225 @default.
• W2023355225 hasPrimaryLocation W20233552251 @default.
• W2023355225 hasRelatedWork W1973049774 @default.
• W2023355225 hasRelatedWork W1985965417 @default.
• W2023355225 hasRelatedWork W1986775667 @default.
• W2023355225 hasRelatedWork W2030768859 @default.

• next